Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 9Gynecologic 2Genitourinary 2Head & Neck 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 77Kidney Neoplasms 23Prostatic Neoplasms 22Neoplasm Metastasis 13Colorectal Neoplasms 10Neoplasms 8Melanoma 7Carcinoma, Transitional Cell 6Breast Neoplasms 6Urinary Bladder Neoplasms 5Stomach Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Myeloproliferative Disorders 2Multiple Myeloma 2Hereditary leiomyomatosis and renal cell cancer 2Hematologic Neoplasms 2Financial Stress 2Esophageal Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2

Interventions

pembrolizumab 9Nivolumab 6Magnetic Resonance Spectroscopy 3Gemcitabine 3Fluorodeoxyglucose F18 3Cisplatin 3Paclitaxel 2Ipilimumab 2Fluorouracil 2FAPI-46 2Drug Therapy 2Carboplatin 2Bevacizumab 2zenocutuzumab 1ulixertinib 1tislelizumab 1spartalizumab 1seribantumab 1niraparib 1milademetan 1lenvatinib 1entrectinib 1durvalumab 1cemiplimab 1atezolizumab 1alectinib 1abemaciclib 1Specimen Handling 1Ramucirumab 1Quality of Life 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cholangiocarcinoma × Bevacizumab × Genitourinary × Clear all
NCT05007106 2025-08-14

KEYVIBE-005

Merck Sharp & Dohme LLC

Phase 2 Completed
613 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03872947 2025-08-03

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Toray Industries, Inc

Phase 1 Active not recruiting
138 enrolled
DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡